Esperion Therapeutics (ESPR) Tops Q3 EPS by 6c

Esperion Therapeutics (NASDAQ: ESPR) reported Q3 EPS of ($0.37), $0.06 better than the analyst estimate of ($0.43). Revenue for the quarter came in at $34 million versus the consensus estimate of $29.59 million.

For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• SPS Commerce hires Morgan Stanley to explore sale amid activist push - Reuters
• Nike names former Pfizer CFO David Denton as new finance chief